[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Sijts et al., 2001 - Google Patents

The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design

Sijts et al., 2001

Document ID
7952371762053374133
Author
Sijts A
Zaiss D
Kloetzel P
Publication year
Publication venue
Current Molecular Medicine

External Links

Snippet

Proteasomes are multisubunit enzyme complexes that reside in the cytoplasm and nucleus of eukaryotic cells. By selective protein degradation, proteasomes regulate many cellular processes including MHC class I antigen processing. Three constitutively expressed …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Sijts et al. The role of the ubiquitin-proteasome pathway in MHC class I antigen processing: implications for vaccine design
Andersen et al. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL
Sijts et al. The role of the proteasome in the generation of MHC class I ligands and immune responses
Basler et al. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus
Tsai et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
Pogue et al. Amino-terminal alteration of the HLA-A* 0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.
Kloetzel The proteasome and MHC class I antigen processing
JP4272201B2 (en) HLA-binding peptide and use thereof
JP6006265B2 (en) HLA-DR binding peptides and their use
Stauss et al. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus.
Oliveira et al. The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects
AU2015302930B2 (en) Methods of treating cervical cancer
AU2009225354A1 (en) Incuding cellular immune responses to human papilloma virus using peptide and nuleic acid compositions
KR20080052647A (en) Human Leukocyte Antigen (HLA) Type I or II Molecular Binding Tumor Related Peptides and Related Anticancer Vaccines
Melief et al. Potential immunogenicity of oncogene and tumor suppressor gene products
Cao et al. Recognition of an immunoglobulin VH epitope by influenza virus-specific class I major histocompatibility complex-restricted cytolytic T lymphocytes.
Montoya et al. Intracellular rate-limiting steps in MHC class I antigen processing
JP2018517405A (en) Influenza A / Shanghai / 2/2013 modified H7 hemagglutinin glycoprotein of H7 sequence
CA2392764A1 (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
Medina et al. Furin-processed antigens targeted to the secretory route elicit functional TAP1−/− CD8+ T lymphocytes in vivo
Cao et al. The weak CD8+ CTL response to an influenza hemagglutinin epitope reflects limited T cell availability.
JP2009273377A (en) Method for selecting candidate peptide presented on surface of cancer cell following binding to mhc class i molecule
Smyth et al. Cd8 T‐cell recognition of human 5T4 oncofetal antigen
US20160331818A1 (en) Novel antigen peptide and uses thereof
CA2393662A1 (en) Inducing cellular immune responses to p53 using peptide and nucleic acid compositions